Category: Accesswire

Smart Spatial Announces Enterprise Digital Twin Deployments to Be Showcased at NVIDIA GTC 2026

Partner demonstrations span product storytelling, simulation planning, and operational training across Unreal Engine and NVIDIA Omniverse

SAN FRANCISCO, CA / ACCESS Newswire / March 2, 2026 / Smart Spatial today announced enterprise digital twin deployments that will be showcased by multiple partners at NVIDIA GTC 2026 (March 16-19). Built across Unreal Engine and NVIDIA Omniverse, these deployments bring products, systems, and infrastructure into interactive, real-time 3D environments built for both visualization and operational use.

Smart Spatial works with leading enterprises, including Schneider Electric, Hewlett Packard Enterprise, Motivair, ZutaCore, DDC Solutions, and others, to build and deploy digital twins that help teams present, test, and operate complex products and infrastructure in interactive 3D. As enterprise investment in AI and simulation accelerates, organizations are placing greater emphasis on digital assets that can be used beyond static rendering.

A digital twin is a virtual model of a product, system, or environment that allows teams to simulate changes, evaluate performance, and identify issues before making decisions in the real world. According to McKinsey & Company, digital twins can reduce development time by up to 50% and improve operational performance by 20-30% in complex industrial environments. At GTC 2026, partner showcases featuring Smart Spatial deployments will demonstrate how these capabilities are being applied in real-world enterprise settings.

“Enterprises no longer want separate 3D assets for sales demos, simulation, and operations,” said Arthur Alter, CRO of Smart Spatial. “They want a repeatable pipeline that supports all three. Our Digital Twin OS helps make that practical across teams and deployments.”

At GTC 2026, Smart Spatial-powered deployments will be featured across three core enterprise applications: marketing and go-to-market, simulation and planning, and operations and training.

Marketing and go-to-market: Interactive Unreal Engine experiences used in executive briefings, trade shows, and customer engagements to communicate complex products and systems in real time.

Simulation and planning: NVIDIA Omniverse-based digital twins used for physics-based simulation, scenario testing, and pre-deployment validation.

Operations and training: Interactive 3D environments that support workforce training, service workflows, and ongoing system management.

At GTC, Smart Spatial is supporting deployments with Schneider Electric, Hewlett Packard Enterprise, Motivair, ZutaCore, DDC Solutions, and other enterprise organizations. These organizations are using Unreal Engine for immersive product storytelling and NVIDIA Omniverse for digital twin workflows used for simulation and planning on NVIDIA GPU infrastructure.

One featured example at GTC 2026 is Schneider Electric’s simulation demonstration built in NVIDIA Omniverse, highlighting a growing enterprise priority: digital assets designed for physics-based simulation, not just visualization. Smart Spatial’s Digital Twin OS supports this shift by helping organizations structure, deploy, and scale digital twin experiences across commercial, engineering, and operational teams.

“Enterprise teams are under pressure to make the same 3D assets work across product demos, simulation, and operations,” said Dennis Khvostionov, CTO of Smart Spatial. “The technical challenge is not just rendering quality – it’s building a repeatable pipeline that keeps data, interactions, and performance aligned across environments. Smart Spatial’s Digital Twin OS is designed to make that deployment workflow practical across Unreal Engine and NVIDIA Omniverse.”

Smart Spatial’s deployments will be live across partner showcases at NVIDIA GTC 2026, demonstrating how enterprises are moving from visualization-first experiences to simulation-capable, operationally useful 3D environments.

About Smart Spatial

Smart Spatial provides a Digital Twin OS that helps enterprises design, deploy, and scale digital twins across marketing, simulation, and operations. The platform integrates Unreal Engine and NVIDIA Omniverse to create interactive 3D environments built on NVIDIA GPU infrastructure.

For more information, visit smartspatial.com.
For more information about NVIDIA GTC, visit nvidia.com/gtc.
Blog post, visit here.

Media Contact

Kristina Novikova
Kristina@smartspatial.com
Website – www.smartspatial.com

SOURCE: Smart Spatial

View the original press release on ACCESS Newswire

March 2, 2026

Electrovaya Announces Results of Annual Meeting of Shareholders

TORONTO, ONTARIO / ACCESS Newswire / March 2, 2026 / Electrovaya Inc. (“Electrovaya” or the “Company”) (NASDAQ:ELVA)(TSX:ELVA),a lithium-ion battery technology and manufacturing company, is pleased to announce that all of the resolutions that shareholders were asked to consider at its 2025 Annual General Meeting held on February 27, 2026 in Toronto, Ontario, were approved. The six directors named in the management information circular of the Company, being Dr. Sankar Das Gupta, Dr. Raj Das Gupta, Dr. James Jacobs, Dr. Carolyn Hansson, Mr. Kartick Kumar, and Mr. Steven Berkenfeld were each elected as directors by over 98.7% of the votes cast for and less than 1.3% of the votes withheld at the Meeting for each director individually. Detailed results of the vote are set out below:

Nominee	Votes For	Votes Withheld	Percentage of Votes For	Percentage of Votes Withheld
Dr. Sankar Das Gupta	23,991,627	42,067	99.82%	0.18%
Dr. Carolyn Hansson	23,724,006	309,688	98.71%	1.29%
Dr. James K. Jacobs	23,873,595	160,099	99.33%	0.67%
Mr. Kartick Kumar	23,869,370	164,324	99.32%	0.68%
Mr. Steven Berkenfeld	24,009,294	24,400	98.82%	1.18%
Dr. Raj DasGupta	24,014,577	19,117	99.92%	0.08%

MNP LLP, were re-appointed as the auditors of the Company.

The special resolution to approve the increase to the options issuable under the Company’s stock option plan was passed with 88.29% voting in favor and 11.71% voting against the resolution.

The special resolution to approve the domestication of the Company to the United States was passed with 99.79% voting in favor and 0.21% voting against the resolution.

Additional details areincluded in the report of voting results filed under the Company’s profile on SEDAR at www.sedarplus.ca.

Investor and Media Contact:     

Jason Roy
VP, Corporate Development and Investor Relations
Electrovaya Inc.
jroy@electrovaya.com / 905-855-4618

About Electrovaya Inc.

Electrovaya Inc. (NASDAQ:ELVA)(TSX:ELVA) is a technology-driven lithium-ion battery company commercializing its proprietary Infinity Battery Technology, designed for superior safety, longevity, and performance in mission-critical industrial, robotics, defense and energy-storage applications. The Company leverages a strong intellectual-property portfolio and advanced materials expertise to deliver durable, high-value battery solutions to global OEMs and end users. To support growing demand and advancing energy-security and national-security objectives, Electrovaya is expanding U.S. manufacturing through its 52-acre Jamestown, New York site, which includes a 137,000-square-foot facility planned as its first gigafactory. Electrovaya also operates two Canadian sites focused on research, engineering, and product commercialization. For more information, please visit www.electrovaya.com.

SOURCE: Electrovaya, Inc.

View the original press release on ACCESS Newswire

March 2, 2026

Bioxytran, Inc. Reports Positive Phase 1b/2a Clinical Study Results for ProLectin-M, a Broad-Range Antiviral Drug in Mild to Moderate COVID-19

BOSTON, MA / ACCESS Newswire / March 2, 2026 / Bioxytran, Inc. (OTCQB:BIXT), a clinical-stage biotechnology company developing carbohydrate-based therapeutics, today announced results from a randomized, double-blind, placebo-controlled Phase 1b/2a clinical study evaluating oral ProLectin-M in hospitalized patients with mild to moderate COVID-19 caused by SARS-CoV-2.

The study showed that the highest evaluated dose of ProLectin-M (16,800 mg/day) was associated with statistically significant earlier viral clearance and faster clinical improvement by Day 5 compared with placebo, while demonstrating a favorable safety and tolerability profile. By Day 7, viral clearance was observed across all study arms, consistent with the expected natural resolution of infection in this population, indicating the treatment effect may be related to accelerating viral clearance. No serious adverse events were reported, and no treatment-related discontinuations occurred.

“We believe an oral, well-tolerated antiviral with a differentiated mechanism could address important gaps in current treatment approaches, particularly in early-stage respiratory infections.” said Dr. Leslie Ajayi, Bioxytran’s Chief Medical Officer. “Our clinical data suggests ProLectin-M demonstrated earlier reductions in viral shedding compared with placebo with a favorable safety profile, and these findings support further evaluation of ProLectin-M in larger, well-controlled studies to assess its potential role as a first-line therapy.”

“These findings provide confirmation of an early clinical trials antiviral effect and support further evaluation of ProLectin-M’s novel galectin-targeting mechanism,” said David Platt, PhD, CEO of Bioxytran. “The clinical trials results are opening a new horizon for a new generation of safe anti-viral drugs. We believe the consistency of the observed activity supports continued clinical development of this oral therapeutic approach.”

Study Design

The Phase 1b/2a study enrolled 39 participants in India with RT-PCR-confirmed SARS-CoV-2 infection and mild to moderate disease. Participants were randomized to receive one of three dose levels of ProLectin-M plus standard of care (SOC), or placebo plus SOC, administered over five days.

Dose Arms:

5,600 mg/day ProLectin-M + SOC, 11,200 mg/day ProLectin-M + SOC, 16,800 mg/day ProLectin-M + SOC, Placebo + SOC.

The primary endpoint evaluated absence of detectable viral RNA at Day 7. Secondary endpoints included earlier viral clearance, changes in viral load, clinical status improvement, safety, and pharmacokinetics.

Key Findings

Earlier Viral Clearance (Day 5)

90% of participants receiving 16,800 mg/day achieved non-detectable viral shedding by Day 5. It was compared with 20.0% (placebo), 20.0% (5,600 mg), and 40.0% (11,200 mg). The difference between the 16,800 mg/day cohort and placebo was statistically significant (p=0.001).

Clinical Improvement

90% of participants in the highest-dose cohort achieved at least a 2-point improvement on the WHO Ordinal Scale by Day 5 compared with 20.0%, 40.0%, and 20.0% in the lower-dose and placebo groups. All participants improved clinically by Day 7.

Viral Load Trends

Cycle threshold (Ct) values increased over time across all groups, consistent with declining viral load. Numerically earlier Ct increases were observed in the highest-dose cohort beginning as early as Day 3, supporting the observed Day-5 antiviral signal.

Primary Endpoint Outcome

Because mild-to-moderate COVID-19 in this population typically resolves within 7 days, the primary endpoint at Day 7 did not differentiate treatment arms. However, earlier viral clearance observed at Day 5 suggests a potential acceleration of viral resolution.

Safety and Tolerability

ProLectin-M was well tolerated at all evaluated dose levels with no serious adverse events, no treatment-related discontinuations, no clinically meaningful changes in laboratory values, ECGs, or vital signs. High compliance with the 5-day dosing regimen.

Development Context

ProLectin-M is designed to target galectins, carbohydrate-binding proteins that certain viruses utilize to attach to and enter host cells. By acting on host-virus interactions rather than intracellular viral replication, this approach represents a differentiated antiviral strategy that may have applicability across multiple viral infections. In future studies, ProLectin-M may also be evaluated for its potential as a preventive therapy. The Company believes these results support continued evaluation of ProLectin-M as a potential oral therapeutic and provide a foundation for future clinical studies.

About ProLectin-M

ProLectin-M is an investigational oral antiviral being developed under an active U.S. Investigational New Drug (IND) framework as well as international regulatory oversight. The therapy leverages carbohydrate chemistry to block viral entry mechanisms mediated by galectin interactions.

About Bioxytran, Inc.

Bioxytran, Inc. is a clinical-stage biotechnology company focused on developing novel carbohydrate-based therapeutics to address significant unmet medical needs in infectious and cardiovascular diseases.

Forward-Looking Statements
This press release includes forward-looking statements as defined under federal law, including those related to the performance of technology described in this press release. These forward-looking statements are generally identified by the words “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” and similar expressions, although not all forward-looking statements contain these identifying words. Such statements are subject to significant risks, assumptions and uncertainties. Known material factors that could cause Bioxytran’s actual results to differ materially from the results contemplated by such forward-looking statements are described in the forward-looking statements and risk factors in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and those risk factors set forth from time-to-time in other filings with the Securities and Exchange Commission. Bioxytran undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events, or otherwise, except to the extent required under federal securities laws.

For more information, please visit:
www.bioxytraninc.com

Investor Contact:
David Platt, PhD
CEO, Bioxytran, Inc.
617-484-1199
David.Platt@bioxytraninc.com

SOURCE: BioXyTran, Inc.

View the original press release on ACCESS Newswire

March 2, 2026
February CAPS / Harris Poll: Trump’s State Of The Union Address Gets A 60% Favorable Rating, With All 11 New Policies Receiving Majority Support
52% OF VOTERS SAY ECONOMY IS BETTER TODAY THAN UNDER BIDEN, UP 5 PTS. FROM JANUARY

65% OF VOTERS AGREE WITH THE SUPREME COURT’S DECISION LIMITING EXECUTIVE POWER TO IMPOSE TARIFFS IN NON-EMERGENCIES

85% OF VOTERS SAY ONLY U.S. CITIZENS SHOULD BE ALLOWED TO VOTE WITH 71% SUPPORTING THE SAVE AMERICA ACT

THE MIDTERMS HORSERACE IS TIED, BUT REPUBLICANS HAVE A 4-PT. MESSAGING EDGE AMONG LIKELY VOTERS

76% OF AMERICANS SUPPORT FREE ENTERPRISE OVER SOCIALIST POLICIES, WITH STRONG CONSENSUS FOR PRIVATE HOMEOWNERSHIP, PROPERTY RIGHTS, AND PRIVATELY RUN GROCERY STORES

59% OF VOTERS NOW SUPPORT MADURO’S ARREST AND VENEZUELA INTERVENTION, A 5-PT. INCREASE, AND 62% SAY TRUMP ADMINISTRATION SHOULD PUSH VENEZUELA TOWARDS DEMOCRACY

NEW YORK, NY and CAMBRIDGE, MA / ACCESS Newswire / March 2, 2026 / Stagwell (NASDAQ: STGW) today released the results of the February Harvard CAPS / Harris poll, a monthly collaboration between the Center for American Political Studies at Harvard (CAPS) and the Harris Poll and HarrisX.

President Donald Trump’s approval rating is at 46%, showing slight improvements across nearly every policy area. His job approval is highest on fighting crime in America’s cities (51%), immigration (48%), and returning America to its values (48%); and lowest on responding to anti-ICE protests in Minneapolis (42%) and tariffs and trade policy (43%). This month’s poll also covered public opinion on the State of the Union, overall economy, midterms, recent Supreme Court ruling, voter ID requirements, economic ideology, and U.S. foreign policy in Latin America, the Middle East, and Ukraine. We will release a special follow-up report later this week on the conflict in Iran. Download the key results here.

“The Americans are single-mindedly focused on the economy, and this poll shows there is room for people to change their opinion as we’re seeing some improvement in the long-term trend,” said Mark Penn, Co-Director of the Harvard CAPS / Harris poll and Stagwell Chairman and CEO. “The administration has to keep working on explaining its economic policy to change the minds of voters ahead of the midterms.”

SLIGHT IMPROVEMENT IN PERCEPTIONS OF THE ECONOMY
- 51% of voters say the U.S. economy is strong today (+2 pts., Jan. 2026; +8 pts., Nov. 2025).
- 36% of voters say their personal financial situation is improving (+4 pts., Nov. 2025), particularly among Republican, male, likely midterm, 25-44 y.o., and urban voters.
- 52% of voters say the economy is better today than it was when Biden was president (+5 pts., Jan. 2026). 59% attribute today’s economy to Trump (Democrats: 75%; Republicans: 44%; Independents: 58%).
- 52% of voters say the economy is shrinking (-4). 62% think inflation is above 3 percent, including a majority across political parties (-4).
VOTERS CONTINUE TO SUPPORT MOST OF TRUMP’S POLICIES
- The majority of key Trump policies continue to see majority support. His most popular policies are lowering prescription drug prices (80% support), deporting illegal immigrants who have committed crimes (75%), eliminating fraud in government expenditures (71%), and capping credit card interest rates at 10% for one year (69%).
- Trump’s least popular policies include removing information about civil rights and climate change from public sites (32% support), Medicaid cost cuts (42%), and hiring additional ICE agents to conduct immigration raids (45%).
- Inflation and immigration continue to be the nation’s top two most important issues today, according to voters, with healthcare increasing in salience this month (+3).
- The Republican Party approval rating is at 48% (+4 pts., Jan. 2026), while the Democratic Party approval rating is at 45% (+1). Congressional approval is at 34% (+2).
FAVORABLE RESPONSE TO STATE OF THE UNION WITH NEW TRUMP POLICIES SEEING STRONG SUPPORT
- 47% of voters say they watched the State of the Union address, with 60% who watched at least some of the address having a favorable opinion of it.
- All 11 of Trump’s new policies announced in the address received majority support, with the most popular being a stock trading ban on Congressional members (72%), federal accounts for employees without retirement plans (70%), a ban preventing single-family home purchases from Wall Street firms (69%), and a most-favored-nation drug pricing deal (68%).
- 52% of voters say it was appropriate for some Democrats to boycott the address, but 57% say their booing and jeering was inappropriate.
- 33% of voters watched the Democratic rebuttal speech by Virginia governor Abigail Spanberger, with 61% who watched at least some of the speech having a favorable opinion of it.
REPUBLICANS GAIN EDGE POST-EXPOSURE TO PARTY MESSAGING IF CONGRESSIONAL ELECTIONS WERE HELD TODAY
- Voters are split 50-50 on which party they would vote for if the congressional election were held today (Republicans +4 pts., Jan. 2026).
- When given statements about party messaging, Republican messaging on responsible governance via curbed spending, closed borders, and reduced crime resonates most, with more than 2 in 5 voters, a plurality, saying the messages make them more likely to vote Republican.
- Anti-Trump messaging from Democrats is more effective than affordability messaging, with 61% of voters saying messages on stopping Trump and his tariffs are believable. However, the message only delivers a net +2 boost in likely vote choice toward Democrats.
- After exposure to each party’s messaging, 51% of voters say they are more likely to vote for a Republican for Congress than a Democrat. The Republican lead grows to 4 pts. among likely voters.
VOTERS AGREE WITH SUPREME COURT RULING AGAINST TRUMP’S TARIFFS
- 65% of voters agree with the Supreme Court’s ruling limiting Trump’s power to impose global tariffs without congressional approval, including a majority across political parties.
- 62% of voters say fentanyl/drug trafficking and large U.S. trade deficits are real issues and emergencies facing the country (Democrats: 43%; Republicans: 81%; Independents: 59%), but 42%, a plurality, say the president should not have authority to impose tariffs in non-emergency situations.
- 56% of voters oppose Trump’s new 15% global tariff after the Supreme Court ruling.
- 51% of voters oppose Trump’s tariffs imposed last year, with 54% saying the tariffs went too far.
MOST VOTERS BACK THE SAVE AMERICA ACT, BELIEVING ONLY U.S. CITIZENS SHOULD BE ALLOWED TO VOTE
- 58% of voters believe there is at least some voter fraud in U.S. elections, particularly among Republicans (77%) and Independents (58%), despite 60% saying the elections are generally secure.
- 85% of voters say only U.S. citizens should be allowed to vote, including a strong majority across political parties.
- 71% of voters support the SAVE America Act (Democrats: 50%; Republicans: 91%; Independents: 69%), with 54% prioritizing stopping voter fraud over access concerns for eligible citizens.
- The majority of voters support specific requirements of the Act, including proof of citizenship (75%), voter ID (81%), states removing non-citizens from voter rolls (80%), and states sharing redacted voting rolls with the Department of Homeland Security (61%).
- 73% of voters say we should have a national law requiring all ballots to be counted within 24 hours of Election Day.
- 68% of voters support early voting, including a majority across political parties.
AMERICANS ARE OVERWHLEMINGLY PRO-FREE ENTERPRISE
- 76% of voters say America should be run as a free enterprise country, including a strong majority across political parties, and 78% believe they have a better life under such a system.
- 59% say capitalism is a better economic system than socialism (Democrats: 46%; Republicans: 74%; Independents: 57%).
- 91% of voters support private homeownership, private property rights, and freedom of opinion. 84% believe grocery stores should be privately run.
- 65% of voters believe the people own their own houses, not the state, under socialism, including a majority across political parties.
- 52% of voters say teachers’ unions are heavily involved in politics, with most viewing them as in the political center (41%) or left-leaning (37%). 60% say they should not be involved in political issues (Democrats: 50%; Republicans: 63%; Independents: 66%).
MAJORITY SUPPORT FOR TRUMP’S GAZA DEAL
- 73% of voters support Trump’s deal to secure the safe return of Israeli hostages and end hostilities in Gaza (+6), including a majority across political parties and age groups.
- 71% of voters continue to support Israel over Hamas in the conflict.
MORE VOTERS SUPPORT MADURO’S ARREST VERSUS LAST MONTH, WANT MORE AGGRESSIVE U.S. STANCE AGAINST DICTATORS AND DRUG CARTELS
- 59% of voters support the arrest of Nicolás Maduro (+5), with 58% saying his removal was in the national interest of the U.S. (+7; Democrats: 41%; Republicans: 79%; Independents: 52%).
- 54% of voters say the U.S. should try to fix the Venezuelan oil industry (-3), though 51% say the U.S. is not entitled to proceeds.
- 62% of voters believe pushing Venezuela towards a democratic transition should be a key priority for the Trump administration, including a majority across political parties.
- 67% of voters say the U.S. should take a more aggressive stand in our hemisphere against leaders propped up by drug cartels, and 62% support a U.S. maximum pressure campaign on the government of Mexico to fight drug cartels.
- 66% of voters think the U.S. should take a more aggressive stance against dictators propped up by Russia and China (+5).
MAJORITY OF VOTERS WANT THE U.S. TO CONTINUE SUPPORTING UKRAINE
- 66% of voters say Trump should continue to provide weapons to Ukraine and impose further economic sanctions on Russia, including a majority across political parties.
- 63% of voters say Ukraine should receive direct security guarantees from the U.S. if it makes concessions to end the war.
- 51% of voters support Trump’s handling of the Ukraine-Russia conflict so far.
The February Harvard CAPS / Harris poll survey was conducted online within the United States on February 25-26, 2026, among 1,999 registered voters by The Harris Poll and HarrisX. Follow the Harvard CAPS / Harris poll podcast at https://www.markpennpolls.com/ or on iHeart Radio, Apple Podcasts, Spotify, and other podcast platforms.

About The Harris Poll & HarrisX

The Harris Poll is a global consulting and market research firm that strives to reveal the authentic values of modern society to inspire leaders to create a better tomorrow. It works with clients in three primary areas: building twenty-first-century corporate reputation, crafting brand strategy and performance tracking, and earning organic media through public relations research. One of the longest-running surveys in the U.S., The Harris Poll has tracked public opinion, motivations, and social sentiment since 1963, and is now part of Stagwell, the challenger holding company built to transform marketing.

HarrisX is a technology-driven market research and data analytics company that conducts multi-method research in the U.S. and over 40 countries around the world on behalf of Fortune 100 companies, public policy institutions, global leaders, NGOs and philanthropic organizations. HarrisX was the most accurate pollster of the 2020 U.S. presidential election.

About the Harvard Center for American Political Studies
The Center for American Political Studies (CAPS) is committed to and fosters the interdisciplinary study of U.S. politics. Governed by a group of political scientists, sociologists, historians, and economists within the Faculty of Arts and Sciences at Harvard University, CAPS drives discussion, research, public outreach, and pedagogy about all aspects of U.S. politics. CAPS encourages cutting-edge research using a variety of methodologies, including historical analysis, social surveys, and formal mathematical modeling, and it often cooperates with other Harvard centers to support research training and encourage cross-national research about the United States in comparative and global contexts. More information at https://caps.gov.harvard.edu/.

Contact:
Carrie Hsu
pr@stagwellglobal.com

SOURCE: Stagwell

View the original press release on ACCESS Newswire
March 2, 2026
Gladstone Alternative Income Fund Announces Monthly Cash Distribution for March 2026

MCLEAN, VA / ACCESS Newswire / March 2, 2026 / Gladstone Alternative Income Fund (“Gladstone Alternative” or the “Fund”) announced today that its board of trustees declared monthly cash distributions to shareholders for the month of March. The March distribution amount is $0.001967 per calendar day for each issued and outstanding Class A share, Class C share, and Class I share for the period beginning March 1, 2026 and ending March 31, 2026 (for shareholders who own shares all 31 days in March, the distribution will total approximately $0.061 per share). Based on net asset values per share as of February 27, 2026, the March distribution amount represents an annualized distribution rate of 7.23% for Class A shares, 7.30% for Class C shares, and 7.21% for Class I shares. The distributions will be paid on March 31, 2026 for Dividend Reinvestment Plan (“DRIP”) participants and April 1, 2026 for non-DRIP participants.

John Sateri, President of Gladstone Alternative, noted, “We continue to focus on raising additional capital to allow us to grow Gladstone Alternative’s investments and generate sustainable returns for our shareholders while providing them access to a diversified portfolio of private credit and equity investments.”

About Gladstone Alternative Income Fund

Gladstone Alternative Income Fund is a non-diversified, unlisted, closed-end management investment company registered under the Investment Company Act of 1940 and is operating as an interval fund. The Fund seeks to achieve and grow current income by investing primarily in directly originated loans to lower and middle market private businesses in the United States, broadly syndicated loans and commercial real estate loans.

Investors are advised to carefully consider the investment objectives, risks and charges, and expenses of Gladstone Alternative Income Fund before investing. The prospectus, dated July 29, 2025, which has been filed with the U.S. Securities and Exchange Commission, and as supplemented from time to time, contains this and other information about the Fund and should be read carefully before investing. You may get these documents for free by visiting the Fund’s website at www.gladstoneintervalfund.com or by visiting EDGAR on the SEC’s website at www.sec.gov. To obtain a copy of the prospectus, you may also contact Gladstone Securities, LLC, the dealer manager and distributor for this offering, which will arrange to send you the prospectus if you request it by calling toll-free at (833) 849-5993.

For further information, please visit our website at www.gladstoneintervalfund.com.

SOURCE: Gladstone Alternative Income Fund

View the original press release on ACCESS Newswire

March 2, 2026
DIGITAL Co-Invests $4.0M in Novamera’s Surgical Mining Technology to Strengthen North American Critical-Minerals Supply

Accelerating Domestic Copper and Rare Earth Production with New AI-Powered, Low-Impact Mining Solution

TORONTO, ON / ACCESS Newswire / March 2, 2026 / DIGITAL has committed $4.0 million in co-investment to support the development of the next phase (“Project”) of Novamera Inc.’s (“Novamera”) Surgical Mining^™ technology, an AI-powered, low-impact mining method designed to unlock domestic critical-mineral resources across North America. The investment will advance copper and REE technology applications and establish a First-of-a-Kind (FOAK) permitting pathway in Ontario, creating a scalable model for faster, lower-risk mine development.

Securing reliable, domestic sources of critical minerals is a strategic priority for Canada. Electrification, defence modernization, and digital infrastructure advancements demand copper and rare-earth elements (REEs). At the same time, traditional mining approaches struggle to bring new supply online to meet current demands. Copper alone is projected to face a significant global supply gap within the next decade, potentially heightening risks to North American manufacturing, energy security, and industrial competitiveness.

While North America hosts extensive known mineral deposits, many remain stranded due to long permitting timelines, high capital requirements, and access challenges presented by narrow, deep, or remote deposit veins. Led by Novamera, in partnership with Northstar Gold Corp. and Micon International, the project aims to demonstrate a practical pathway to accelerate domestic production on a copper deposit while materially reducing the environmental footprint and upfront capital requirements.

Novamera’s patented Surgical Mining solution integrates advanced subsurface imaging, AI-driven simulation, robotics, and conventional drilling equipment to precisely target mineralized zones. By selectively extracting ore and minimizing waste, the technology enables faster time-to-production and minimal environmental disturbance.

“North America has no shortage of critical minerals-we have a shortage of ways to bring them into production quickly and responsibly,” said Jim Hollis, CEO, Novamera Inc. “Surgical Mining was built to solve that gap. With DIGITAL’s support, we’re accelerating a solution that can unlock domestic copper and rare earth supply faster, with lower capital and a far smaller environmental footprint.”

“Mining is foundational to Canada’s prosperity and long-term economic resilience,” said Sue Paish, CEO of DIGITAL. “We’re proud that our first co-investment with Novamera supported the development of ‘Surgical Mining’ to unlock access to narrow vein copper and rare earth deposits. This next phase will advance the technology to increase Canada’s supply of critical minerals while reducing surface disruption and risk. Defence readiness and industrial competitiveness go hand in hand. By investing in Canadian companies such as Novamera, and accelerating the adoption of homegrown innovation, we will build more resilient supply chains, develop and retain intellectual property, and create high-quality jobs for Canadians.”

The co-investment builds on Novamera’s successful completion of a prior DIGITAL-supported project in 2025. That project-delivered in partnership with Memorial University of Newfoundland and two junior mining companies in Newfoundland-validated the Surgical Mining process under real-world conditions. It demonstrated key innovations in three-dimensional position control and real-time visualization, as well as key economic and environmental performance metrics that have since driven commercial adoption, reinforcing the technology’s readiness for broader North American deployment. A detailed case study will be released in the coming weeks.

For more information, including videos and images of the Surgical Mining process, please contact:
Theresa Quick, Chief Revenue Officer, Novamera Inc. innovation@novamerainc.com

About Novamera

Founded in 2019, Novamera is revolutionizing how the world mines. Its patented Surgical Mining process enables precise, low-impact extraction of previously uneconomic narrow-vein deposits. By combining advanced subsurface imaging, AI-driven orebody modelling, and precision robotic extraction, Novamera helps mining companies unlock new resources with lower costs, faster timelines, and minimal environmental impact-creating a new category of sustainable, high-return projects.

About DIGITAL

DIGITAL connects technology builders and buyers to accelerate the adoption and commercialization of Canadian solutions. Established in 2018 under the Government of Canada’s Supercluster Initiative, DIGITAL brings together industry leaders, SMEs, and post-secondary institutions to collaborate on large-scale projects that drive innovation and the development of technology solutions in sectors critical to Canada, such as mining and energy, housing, workforce development and health.  

Since inception, DIGITAL has delivered billions in projected revenue for Canadian companies, retained sovereign IP, launched hundreds of commercial products, and helped tens of thousands of Canadians gain the skills needed for the digital economy. digitalsupercluster.ca

SOURCE: Novamera

View the original press release on ACCESS Newswire

March 2, 2026
Optimal Dynamics Launches Scale, the First Decision-Native Agentic System(TM) Built to Proactively Secure the Right Freight

Scale continuously determines where freight is needed to balance carrier networks and deploys intelligent autonomous agents to secure it in real time.

NEW YORK CITY, NEW YORK / ACCESS Newswire / March 2, 2026 / Optimal Dynamics, the pioneer of Transportation Decision Systems (TDS), today announced the launch of Scale, the industry’s first Decision-Native Agentic System^™ (DNAS), a new class of software that unifies optimization intelligence and autonomous agents to drive profitable growth, network balance, and high service levels.

Unlike traditional agentic tools that react to individual requests or operate in isolation, Scale is built around a decision optimization engine that continuously understands a carrier’s network. It identifies where capacity is constrained, where imbalance is developing, and where additional freight is proactively needed to improve utilization, service, and profitability.

From that foundation, Scale deploys an always-on, autonomous agentic workforce that operates continuously on a customer’s behalf. It searches, negotiates, bids, and procures freight across load boards, direct shipper channels, email, and EDI, aggregating opportunities across multiple sources into a single execution layer. This decision-native foundation determines which freight should be secured, from where, and when it should move, to keep the network balanced and ensure every action directly supports the network’s strategic needs.

“As a carrier, the hardest part isn’t finding freight, it’s knowing which freight actually improves your network,” said Karen Smerchek, President at Veriha Trucking. “With Scale, we expect to move from reactive decision-making to a system that continuously tells us where freight is needed ahead of time, and then works the market to secure it. Shifting towards proactive, network-aware procurement will help us stay balanced and profitable as conditions change.”

Breaking the “Accept Everything” Trap

“In today’s market, the pressure to accept more freight is intense, but accepting the wrong freight creates downstream problems,” said Daniel Powell, CEO of Optimal Dynamics. “Carriers don’t just need automation; they need a system that understands their network and proactively works to improve it. Scale makes smarter decisions earlier in the order lifecycle, where imbalance and profit erosion often begin.”

Traditional freight procurement relies on manual effort, gut feel, or reactive tools that treat each load as a standalone decision. Scale replaces this approach with a shared decision system that continuously aligns revenue growth with utilization, service performance, and profitability.

By proactively identifying where freight is needed, and autonomously working the market to secure it, Scale helps carriers avoid costly deadhead, protect service commitments, and grow profitably.

Optimization Decides. Agents Act.

While conventional agents follow learned patterns or scripted workflows, Scale is decision-native by design. Optimal Dynamics’ core optimization engine continuously evaluates opportunities across the entire network. In parallel, the Atlas agentic layer executes the necessary actions by sourcing, negotiating, or declining freight autonomously and at scale.

This tight coupling of decision intelligence and execution ensures that Scale’s agents are not just fast, but intentional, coordinated, and operationally sound.

“What excites us most about Scale is the idea of an always-on agentic workforce that’s working for us across load boards, direct channels, and inbound requests at the same time,” said Michael McGovern, Chief Operating Officer at Leonard’s Express. “Instead of our team chasing opportunities manually, we expect Scale’s agents to aggregate freight from many places, act autonomously, and secure the loads that align with our network strategy without us having to intervene on every decision.”

With the launch of Scale, Optimal Dynamics completes the third and most critical component of the industry’s first comprehensive Transportation Decision System (TDS). Together, these components form a decision-native architecture that bridges the gap between optimization and execution by delivering real-time actions that keep carrier networks balanced and profitable.

Optimal Dynamics will showcase Scale live at the TCA Annual Convention in Orlando. Attendees are invited to visit Booth #409 to see the Decision-Native Agentic System (DNAS)^™ in action and learn how proactive, autonomous freight procurement can transform network performance. To request a personalized demo, visit www.optimaldynamics.com.

About Optimal Dynamics

Optimal Dynamics, the pioneer of Transportation Decision Systems (TDS), provides the decision intelligence layer that powers logistics transformation. Built on more than 40 years of research originating at Princeton University, Optimal Dynamics uses a proprietary decision-native architecture to automate, optimize, and scale trucking and transportation operations. Headquartered in New York City, the company is backed by Koch Disruptive Technologies, Bessemer Venture Partners, The Westly Group, and Activate Capital. Learn more at www.optimaldynamics.com.

CONTACT:
Erica Frank
SVP of Marketing
efrank@optimaldynamics.com
917-382-4431

SOURCE: Optimal Dynamics

View the original press release on ACCESS Newswire

March 2, 2026
Reminder: Today, March 2, 2026, is the Record Date for Jaguar Health’s Special One-time Stock Dividend

Dividend intended to provide dilution protection to Jaguar shareholders as company explores pathway to restructure debt

SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / March 2, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar” or “the Company”) today issued a reminder that today, March 2, 2026, is the Record Date for the Company’s one-time special stock dividend (the “Special Stock Dividend”). As announced, in February 2026 Jaguar’s Board of Directors declared a one-time Special Stock Dividend to holders of Jaguar Common Stock and certain outstanding warrants as of record on March 2, 2026. The Special Stock Dividend will consist of the Company’s Series O Convertible Preferred Stock (the “Preferred Stock”).

The payment date for the Special Stock Dividend is March 4, 2026, two days after the Record Date. The dividend will be sent to eligible holders of Jaguar Common Stock and certain outstanding warrants automatically, with no action required by the eligible parties.

“Jaguar is issuing the Special Stock Dividend to reward and recognize our passionate and supportive stockholders and provide protection against potential dilution as we explore pathways to repay and restructure our existing indebtedness,” said Lisa Conte, Jaguar’s founder, president, and CEO. “Jaguar has a sharp strategic focus on our ongoing global development program for our crofelemer powder-for-oral-solution formulation for intestinal failure. As announced, Jaguar was provided with meaningful non-dilutive capital in January 2026 upon entering a U.S. license agreement with Future Pak for Mytesi^®– an agreement that is fully aligned with our strategy to concentrate Jaguar’s crofelemer development efforts on human rare-disease intestinal failure indications.”

The Preferred Stock is not transferable and will not be listed for trading on any stock exchange and will not trade with the Common Stock. For additional information about the Special Stock Dividend and terms of the Preferred Stock and associated risk factors, please refer to the Form 8-K the Company filed with the U.S. Securities and Exchange Commission on February 18, 2026, which can be viewed on the Company’s website by clicking here.

About Crofelemer

Crofelemer is a novel, oral plant-based prescription medicine purified from the red bark sap, also referred to as “dragon’s blood,” of the Croton lechleri tree in the Amazon Rainforest. Napo Pharmaceuticals has established a sustainable harvesting program, under fair trade practices, for crofelemer to ensure a high degree of quality, ecological integrity, and support for indigenous communities.

About the Jaguar Health Family of Companies

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress. Jaguar family companies Napo Pharmaceuticals, Inc. (Napo) and Napo Therapeutics S.p.A. focus on the development and commercialization of novel crofelemer powder for oral solution for the treatment of rare and orphan gastrointestinal disorders with intestinal failure, including microvillus inclusion disease and short bowel syndrome.

For more information about:

Jaguar Health, visit https://jaguar.health

Napo Pharmaceuticals, visit napopharma.com

Napo Therapeutics, visit napotherapeutics.com

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements.” These include statements regarding payment of dividends. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contact:

hello@jaguar.health

Jaguar-JAGX

SOURCE: Jaguar Health, Inc.

View the original press release on ACCESS Newswire

March 2, 2026
Stagwell Launches Stagwell Search+: The Industry’s First Agentic Platform To Win AI Search
New media solution enables brands to win discoverability, visibility, positive sentiment, and outcomes across major AI systems

NEW YORK, NY AND LONDON, UK / ACCESS Newswire / March 2, 2026 / Stagwell (NASDAQ:STGW), the global challenger network transforming marketing through AI, today announced the global launch of Stagwell Search+, the industry’s first agentic platform for AI Search experiences. Built by Assembly, Stagwell’s global omnichannel media agency, in partnership with Emberos, the operating system for AI visibility, Stagwell Search+ is a category-defining solution to master the transition from traditional search engines to AI search experiences.

As Large Language Models (LLMs) increasingly mediate how people discover, compare, and choose, Stagwell Search+ helps brands optimize not just for clicks and traffic, but for a new era of search where AI guides decisions and the goal is to be chosen. The solution combines an agentic platform with a differentiated framework that improves a brand’s discoverability, visibility, sentiment, and outcomes in AI Search. Unlike existing industry solutions that treat this as an SEO adjustment, Stagwell Search+ is the first built on the understanding that this is a paid, owned, earned and shared media challenge that demands a system, not simply another stack of isolated channel tactics. Stagwell Search+ unifies four core capabilities for brand performance in AI Search:
- Audit, Assembly’s AI search product, understands and assesses a brand’s activation maturity across media channels.
- Then Assembly’s AI search intelligence layer utilizes Emberos’ unique AI agents to measure discoverability, visibility and sentiment across generative surfaces.
- Combined, the output gives teams the exact strategies to implement a unified, cross-channel system that influences how AI models understand and recommend brands.
- Through continuous measurement and experimentation, Search+ compounds learning and strengthens brand performance over time.
Assembly clients are already adopting Stagwell Search+’s early model and have proven impact in early deployments, including:
- +57% increase in visibility in AI Overviews for a software client.
- +34% increase in revenue from AI-powered search transformation with a global technology client using AI Max, a paid search campaign type in Google Ads, for Search Ads.
- +27% average incremental lift from Search+ system-based activation.
“Stagwell Search+ solves the ‘data-to-execution’ gap that plagues existing tools and delivers best-in-class solutions for clients by enabling them to act on AI search insights in real time with clear results. Building on the launch of The Machine, marketing’s first agentic operating system, this latest development for the media sector continues Stagwell’s momentum as an AI winner,” said Mark Penn, Chairman and CEO of Stagwell.

“The front door of the Internet has changed. LLMs are now how people discover products and make buying decisions. Stagwell gets that-and we’re excited to partner with them to bring Emberos’ AI agents and AI Brand Orchestration infrastructure to their clients so they can win where it matters most,” said Justin Inman, Founder & CEO at Emberos.

This solution comes after a strong year of momentum for Stagwell in AI following the launches of NewVoices.ai, The Machine and Agent Cloud. Assembly also continues to win industry recognition as a global leader in AI-powered performance, including being named Microsoft Advertising Partner of the Year and widely recognized by Google for its AI-first search leadership.

For more information, visit: https://stagwellsearchplus.assemblyglobal.com/

About Stagwell

Stagwell is the global challenger network transforming marketing through AI. We deliver scaled creative performance for the world’s most ambitious brands, connecting culture-moving creativity with leading-edge technology to harmonize the art and science of marketing. Led by entrepreneurs, our specialists in 45+ countries are unified under a single purpose: to drive effectiveness and improve business results for our clients. Join us at www.stagwellglobal.com.

About Assembly

Assembly is a global omnichannel agency built for brands that want a more modern approach to building brands that perform. Backed by the Stagwell network, we are a literal assembly of data, talent, and technology built to unlock smarter, faster, and better-performing outcomes from the bottom up -not the top down. Curious, collaborative, and driven by change, we are an agency of builders who believe the better the experience, the better the performance. We don’t see brand and performance as an either/or. For us, it’s always both. The + symbol in our logo, known as the ORAD, represents this mindset. It’s a mark of how we think, how we build, and how we deliver results across the full funnel. Assembly’s foundation is built on three core elements: our purpose-built STAGE Experience Engine, the strategic product it powers-Brand Performance Planning (BPP) – and an organizational design built for speed, depth, and the demands of modern marketing. Together, they enable us to build better brand experiences that reimagine how brands connect, engage, and grow across data, tech, media, creative and commerce. With over 3,000 experts in 44 offices worldwide, Assembly delivers full-funnel solutions that help the world’s most ambitious brands perform. Learn more at assemblyglobal.com.

About Emberos

Emberos is the operating system for AI visibility. The platform enables studios, enterprises, and consumer brands to see how they appear inside major AI systems, monitor visibility shifts in real time, predict demand, and quantify impact across multiple industries. Learn more at https://www.emberos.ai/

Contact
Quinn Werner
PR@stagwellglobal.com

SOURCE: Stagwell

View the original press release on ACCESS Newswire
March 2, 2026
EDGE Surgical Launches 40mm and 120mm Electronic Depth Gauges

Comprehensive Product Line Now Available for Orthopedic Surgery

BURLINGTON, MA / ACCESS Newswire / March 2, 2026 / EDGE Surgical, Inc., the pioneering force behind the world’s only electronic depth gauge for orthopedic surgery, proudly announces the expansion of its Ortho EDG^® platform with the introduction of the 40mm and the 120mm single-patient use, universal electronic depth gauges. Eliminating the need for reusable depth gauges, EDGE Surgical boasts a complete depth gauge line to address the mini, small and large fragment markets, including tailored solutions for orthopedic specialties like hand and wrist, foot and ankle, craniomaxillofacial and others. The new devices build on the proven success of the previously launched, universal 65mm depth gauge, setting a new standard in surgical precision.

These groundbreaking products will be on display at AAOS.

It’s Time to Take Reusable Depth Gauges out of the Tray

The shortcomings associated with reusable depth gauges-including potential inaccuracy and contamination-are well known and present significant risks that can lead to severe, avoidable complications. These risks no longer have to be accepted. According to a prominent chief of orthopedics in Florida, “We don’t reuse drill bits, we don’t reuse wires-reusing a depth gauge doesn’t make sense.”

Contaminated surgical instruments have led to shutdowns and delays at hospitals nationwide. These shutdowns not only impact patients but restrict healthcare access to the broader local community and burden the taxpayers who help fund these institutions.

It’s no secret why hospitals across the country are adopting state-of-the-art electronic depth gauges from EDGE. Replacing standard depth gauges can reduce cost of care and improve patient outcomes, while also alleviating burden from the overtaxed, under-resourced SPD team struggling to properly clean and sterilize the complicated, reusable depth gauge. Early adopters of the 65mm EDG, including surgeons and hospitals, have seen this value.

“From eight-figure lawsuits to life-changing infections, the stakes for hospitals and patients couldn’t be higher. It’s imperative to remove the reusable depth gauge from the operating room immediately,” said Leo Carayannopoulos, CEO of EDGE Surgical. “Surgeons have struggled, and patients have been put at risk with this antiquated technology long enough. With a complete solution from small to large fragment, EDG reduces risk and helps improve patient outcomes. EDGE is the obvious choice.”

Multiple plate and screw manufacturers have expressed interest in adopting the EDGE product line. From improved surgeon support to offering a competitive advantage in workflow and patient outcomes, EDG presents a strategic opportunity.

Tailored, Surgeon-Designed Solutions

The EDG product family is built with surgeon and industry expert guidance input to address the needs of different surgical specialties. The surgeon-driven design, combined with universal compatibility with all major plate and screw systems, eliminates the need for reusable depth gauges in the surgical tray.

A New, Better Standard of Care

Adopting EDG^® just makes sense. EDGE Surgical is not merely the future of depth gauge technology-it is the depth gauge perfected.

Accurate: Featuring a digital display far more precise than traditional gauges, combined with a patented hook, the EDG ensures accurate measurements the first time, every time.

Sterile: With every device sterile and packaged for single-patient use, EDG eradicates the risk of secondary infections linked to depth gauges, helping to ensure patient safety.

Universal: EDG is compatible with all major plating systems, manufacturers, and screw sizes, eliminating the need for multiple depth gauges.

Universal Compatibility

The Universal Depth Gauge can be easily calibrated to any plating system from major manufacturers, including Depuy Synthes, Zimmer Biomet, Smith & Nephew, Stryker, Acumed, Paragon 28, Globus, Skeletal Dynamics, Arthrex, Medartis, Trimed, Conventus Flower Orthopedics, and more.

Benefits Beyond the OR

EDG is a game-changer. Compatible with all major plate and screw systems, EDG seamlessly fits into existing surgical workflows. With features like dynamic calibration, the Electronic Depth Gauge ensures ease of use and accurate measurements, contributing to better surgical outcomes.

EDG delivers benefits that go far beyond the OR.

Reducing Backups in Sterile Processing

EDG® is for single-patient use, ultimately leading to the elimination of many depth gauges from surgical trays and reducing SPD load. Confusing or non-existent instructions, and hidden nooks, crannies and narrow cannulations make it nearly impossible to reliably clean depth gauges.

Driving Down Secondary Infection Risk while Driving Efficiency

EDG eliminates a point of risk exposure for secondary site infections and assures the risk management and infection prevention teams that their depth gauges are clean.

For OR leadership, EDG^® helps drive efficiency in OR flow and removes potential delays that could impact OR scheduling.

EDGE continues to innovate, developing variants tailored to specialties such as hand and wrist, foot and ankle, lower extremity and others. EDG gives surgeons a sterile, accurate device, no matter the procedure.

The Human Cost of Inaction

The impact of secondary infections and surgical complications extends beyond statistics; they deeply affect individuals, leading to long-term loss of mobility, years of surgeries, physical therapy, and sometimes only partial recovery. EDGE is committed to highlighting these personal stories, bringing attention to the real faces behind these complications and fostering greater awareness of their profound impact. Look for these stories on edgesurcial.com in the weeks to come.

Available for Order at AAOS this week

EDGE Surgical will be showcasing its innovative devices at booth 1003 during the AAOS conference in New Orleans. Attendees will have the opportunity to experience firsthand how the EDG revolutionizes orthopedic practices. The EDGE team will be available to answer questions and discuss how their solutions can enhance surgical precision.

About EDGE Surgical

EDGE Surgical reduces risks and delays in Open Reduction and Internal Fixation (ORIF) surgeries. Its flagship product, the Electronic Depth Gauge (Ortho EDG^®), saves time, saves money, and prevents infections, removing risks associated with traditional reusable depth gauges. The EDG, universally compatible with all major plate and screw systems, uses a digital display and patented hook to deliver consistent and accurate results every time. The single-use device is sterile packaged, eliminating risk of biocontamination.

EDG delivers benefits across the organization by reducing unplanned tray replacement orders for supply chain, relieving SPD of cleaning duties for a difficult instrument, lowering secondary infection liability risk, and helping OR leadership stay on schedule. Visit www.edgesurgical.com for more information.

Media Contact:

Mark Severns
Director of Marketing
EDGE Surgical, Inc.
mark@edgesurgical.com
10 Burlington Mall Rd, Suite 206
Burlington, MA 01803

SOURCE: EDGE Surgical

View the original press release on ACCESS Newswire

March 2, 2026